


We claim:

1. A compound of Formula I:



( I )

or pharmaceutical acceptable salts thereof wherein:

X is  $\text{NR}_1$ ;

$\text{R}_1$  is

- a) H,
- b)  $\text{C}_{1-6}$  alkyl, optionally substituted with one or more OH, CN, or halo,
- c)  $-(\text{CH}_2)_h\text{-aryl}$ ,
- d)  $-\text{COR}_{1-1}$ ,
- e)  $-\text{COOR}_{1-2}$ ,
- f)  $-\text{CO}-(\text{CH}_2)_h\text{-COR}_{1-1}$ ,
- g)  $-\text{SO}_2\text{-C}_{1-6}$  alkyl,
- h)  $-\text{SO}_2\text{-(CH}_2)_h\text{-aryl}$ , or
- i)  $-(\text{CO})_i\text{-Het}$ ;

$\text{R}_{1-1}$  is

- a) H,
- b)  $\text{C}_{1-6}$  alkyl, optionally substituted with one or more OH, CN, or halo,
- c)  $-(\text{CH}_2)_h\text{-aryl}$ , or
- d)  $-(\text{CH}_2)_h\text{-OR}_{1-3}$ ;

$\text{R}_{1-2}$  is

- a)  $\text{C}_{1-6}$  alkyl, optionally substituted with one or more OH, CN, or halo,
- b)  $-(\text{CH}_2)_h\text{-aryl}$ , or
- c)  $-(\text{CH}_2)_h\text{-OR}_{1-3}$ ;

$\text{R}_{1-3}$  is

- a) H,
- b)  $\text{C}_{1-6}$  alkyl,
- c)  $-(\text{CH}_2)_h\text{-aryl}$ , or
- d)  $-\text{CO}(\text{C}_{1-6} \text{ alkyl})$ ;

$\text{R}_2$  is

Q1  
cont

- a) H,  
 b) C<sub>1-6</sub> alkyl,  
 c) -(CH<sub>2</sub>)<sub>h</sub>-aryl, or  
 d) halo;

5 R<sub>3</sub> and R<sub>4</sub> are independently

- a) H, or  
 b) halo;

R<sub>5</sub> is

- a) H,  
 10 b) C<sub>1-12</sub> alkyl, optionally substituted with one or more halo,  
 c) C<sub>3-12</sub> cycloalkyl,  
 d) C<sub>1-6</sub> alkoxy;

Het is 5- to 10-membered heterocyclic rings having one or more oxygen, nitrogen, and sulfur atoms;

15 the dotted line ----- in the ring system of Formula I is a single or a double bound;

h is 1, 2, 3, or 4;

i is 0 or 1;

m is 0, 1, 2, 3, 4, or 5;

n is 0, 1, 2, 3, 4, or 5;

20 and with the following provisos

- a) m and n taken together are 3, 4, or 5;  
 b) where the dotted line ----- is a double bound, R<sub>2</sub> is not present in

Formula I.

25 2. A compound of Claim 1 wherein R<sub>1</sub> is selected from the group consisting of H, fluoroethyl, cyanomethyl, methyl sulfonyl, formyl, hydroxyacetyl, acetyl, methoxyacetyl, benzyloxyacetyl, acetoxyacetyl, dichloroacetyl, methoxy carbonyl, tert-butoxy carbonyl, benzyloxy carbonyl, 3-hydroxypropionyl, 3-methoxypropionyl, 4-oxopentanoyl, 2-indole carbonyl, 5-isoxazole carbonyl, 5-nitro-2-thiazoyl, 4-oxo-2-  
 30 thiazoliny, and 5-methyl-1,3,4-thiadiazol-2-yl.

3. A compound of Claim 1 wherein R<sub>2</sub> is H, F, or CH<sub>3</sub>.

4. A compound of Claim 1 wherein R<sub>3</sub> and R<sub>4</sub> are independently H or F.

35

5. A compound of Claim 1 wherein R<sub>5</sub> is methyl, ethyl, cyclopropyl, or methyl

substituted with one to two F or Cl.

6. A compound of Claim 1 wherein m and n taken together are 3.
7. A compound of Claim 1 wherein m and n taken together are 4.
8. A compound of Claim 1 which is an optically pure enantiomer having the S-configuration at C5 of the oxazolidinone ring.
9. A compound selected from the group consisting of:
- (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinecarboxylic acid phenylmethyl ester;
  - (S)-(-)-N-[[2-Oxo-3-[4-(4-piperidinyl)phenyl]-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-[(Benzyloxy)acetyl]-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-[(Benzyloxy)acetyl]-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-[(Benzyloxy)acetyl]-4-piperidinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-4-piperidinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-(Indole-2-carbonyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-(Isoxazole-5-carbonyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-(Methylsulfonyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperidinecarboxylic acid methyl ester;
  - (S)-(-)-N-[[3-[4-[1-(Cyanomethyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
  - (S)-(-)-N-[[3-[4-[1-(2-Fluoroethyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-

- oxazolidinyl)methyl]acetamide;
- o). (S)-(-)-N-[[3-[4-[1-(Formyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;
- p). (S)-(-)-4-[4-[5-[[2,2-Dichloroacetyl)amino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester;
- 5 q). (S)-(-)-2,2-Dichloro-N-[[2-oxo-3-[3-fluoro-4-(4-piperidinyl)phenyl]-5-oxazolidinyl)methyl]acetamide;
- r). (S)-(-)-2,2-Dichloro-N-[[2-oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-4-piperidinyl]phenyl]-5-oxazolidinyl)methyl]acetamide;
- 10 s). (S)-(-)-2,2-Dichloro-N-[[2-oxo-3-[3-fluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-5-oxazolidinyl)methyl]acetamide;
- t). (S)-(-)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-4-piperidinyl]phenyl]-5-oxazolidinyl)methyl]acetamide;
- u). (S)-(-)-N-[[3-[4-[1-(4-Oxo-2-thiazoliny)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;
- 15 v). (S)-(-)-N-[[3-[4-[1-(4-Oxo-2-thiazoliny)-3,6-dihydro-2H-pyridin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;
- w). (S)-(-)-N-[[3-[4-[1-(5-Methyl-1,3,4-thiadiazol-2-yl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;
- 20 x). (S)-(-)-N-[[3-[4-[1-(5-Methyl-1,3,4-thiadiazol-2-yl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;
- y). (S)-(-)-N-[[2-Oxo-3-[4-(3,6-dihydro-2H-pyridin-4-yl)-3-fluorophenyl]-5-oxazolidinyl)methyl]acetamide;
- z). (S)-(-)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-5-oxazolidinyl)methyl]acetamide;
- 25 aa). (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;
- bb). (S)-(-)-N-[[3-[4-[1-(Formyl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;
- 30 cc). (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,6-dihydro-1(2H)-pyridinecarboxylic acid methyl ester;
- dd). (S)-(-)-N-[[2-Oxo-3-[4-(3,6-dihydro-2H-pyridin-4-yl)phenyl]-5-oxazolidinyl)methyl]acetamide;
- ee). (S)-(-)-N-[[2-Oxo-3-[4-[1-[(acetoxy)acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-5-oxazolidinyl)methyl]acetamide;
- 35 ff). (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]phenyl]-2-oxo-5-

oxazolidinyl)methyl]acetamide;

gg). (S)-(-)-N-[[3-[4-[1-(Formyl)-3,6-dihydro-2H-pyridin-4-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;

hh). (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinecarboxylic acid methyl ester;

ii). (S)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-5,6-dihydro-2H-pyridin-3-yl]phenyl]-5-oxazolidinyl)methyl]acetamide;

jj). (S)-N-[[3-[4-[1-(Hydroxyacetyl)-5,6-dihydro-2H-pyridin-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;

kk). (S)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-2,3,4,7-tetrahydro-1H-azepin-5-yl]phenyl]-5-oxazolidinyl)methyl]acetamide;

ll). (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-2,3,4,7-tetrahydro-1H-azepin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;

mm). (S)-(-)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-2,3,6,7-tetrahydro-1H-azepin-4-yl]phenyl]-5-oxazolidinyl)methyl]acetamide;

nn). (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-2,3,6,7-tetrahydro-1H-azepin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;

oo). (5S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)hexahydro-1H-azepin-4-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;

pp). (S)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-3,4-dihydro-2H-pyridin-5-yl]phenyl]-5-oxazolidinyl)methyl]acetamide;

qq). (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-3,4-dihydro-2H-pyridin-5-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide; and

rr). (S)-(-)-N-[[3-[4-[1-Formyl-4-fluoro-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide.

10. A compound of Claim 9 which is:

a). (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;

b). (S)-(-)-N-[[3-[4-[1-(Formyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide;

c). (S)-(-)-2,2-Dichloro-N-[[2-oxo-3-[3-fluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-5-oxazolidinyl)methyl]acetamide;

d). (S)-(-)-N-[[2-Oxo-3-[3-fluoro-4-[1-[(acetoxy)acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-5-oxazolidinyl)methyl]acetamide;

e). (S)-(-)-N-[[3-[4-[1-(Hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3-fluorophenyl]-

- 5

10

15

13. The method of Claim 11 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

add  
A2

add  
B1